Observational studyThe Journal of investigative dermatology2022
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
Observational study in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04898751 (Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Risk Factors for Cutaneous Immune-Related Adverse Events in the Japanese Population: A Retrospective Single-Center Cohort Study.The Journal of dermatology · 2026Article
- Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.medRxiv : the preprint server for health sciences · 2026Article
- [Management of immune-related cutaneous toxicities].Magyar onkologia · 2025Review
- Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors.Journal of the American Academy of Dermatology · 2025Article
- The Current State and Future Prospects for Artificial Intelligence in Dermatology.Dermatologic clinics · 2025Review
- Immune checkpoint inhibitor-induced dyshidrotic eczema following tremelimumab therapy for hepatocellular carcinoma.JAAD case reports · 2025Article
- Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.JAMA dermatology · 2025Article
- Immune checkpoint inhibitor associated lichenoid dermatitis mimicking erythema multiforme major with a germline variant in human leukocyte antigen-B15.JAAD case reports · 2025Article
- Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model.Clinical and translational science · 2025Article
- Mechanisms Underlying Lichen Planus in Association with Biologic Therapy.Journal of inflammation research · 2025Review
- Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Article
- Article
- Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.The British journal of dermatology · 2024Article
- Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.Journal for immunotherapy of cancer · 2024Article
- Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center.Journal of the American Academy of Dermatology · 2024Article
- Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.Journal of the American Academy of Dermatology · 2023Article
- Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis.Frontiers in pharmacology · 2023Article
- Updates in toxicities associated with immune checkpoint inhibitors.Expert review of clinical immunologyReview
- Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
Abstract
Cutaneous immune-related adverse events (cirAEs) are the most prevalent complication to arise from immunotherapy and cause significant morbidity. We aimed to determine the spectrum, timing, clinical features, and outcomes of cirAEs by conducting an observational pharmacovigilance study using VigiBase, the World Health Organization's global database of individual case safety reports from over 130 member countries (ClinicalTrials.gov, number NCT04898751). We compared adverse event reporting in patients who received immune checkpoint inhibitors (91,323 adverse events) with those of the full reporting database (18,919,358 adverse events). There were 10,933 cases of cirAEs within 51 distinct dermatologic types, with 27 specific eruptions with disproportionate signal represented (information component [IC]
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.